You know that old saw about every med school graduate winning the “Doctor” title? Something similar could apply to Sarepta’s newly approved Duchenne muscular…

A dozen specialty pharmacies made it to this year’s Inc. magazine list of fastest growing private companies in the U.S., including one in the top 10.

Every race car driver has sponsors. But not every sponsor gets the articulate marketing backup that Indy driver Charlie Kimball, who has Type 1 diabetes,…

Sun Pharma licensed a home-grown dengue fever vaccine that it hopes will rival Sanofi's Dengvaxia, which was recently delayed in India.

When Gilead's hep C drugs hit the market, their older rivals went into a tailspin. Now, it's Gilead's time to suffer. The hep C market is once…

The list of drugmakers reportedly eying Bayer’s up-for-sale dermatology unit is growing even longer.

Bad news for Amgen’s first-line Kyprolis ambitions: The med has flopped in its first Phase III study in newly diagnosed multiple myeloma patients.

Johnson & Johnson has a new indication for anti-inflammatory med Stelara--and not a moment too soon.